Healthcare Reform
Obamacare and U.S. Pharma: Two Months In
So, we’ve experienced two months of Obamacare. How is the U.S. pharmaceutical industry doing with this new program? Tom Norton spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, sales, and R&D planning for 2014 and beyond ...Read more
Video
The Biggest Myth in Healthcare
Health care reform is a vexing challenge to all governments. Despite the difficulties of building a consensus for reform, change is inevitable: inaction is not an option. The real question is how to provide high quality care to the patient at an affordable cost? ...View here
Vaccines
Where’s the Vaccine for Meningitis B?
The bacterial meningitis outbreak at Princeton University in recent weeks has raised questions about why there is no vaccine in US to prevent this deadly disease, when such a therapy is approved in Europe and Australia. Ben Comer reports ...Read more
Scivigilance – Pharmacovigilance in a box
Technology and process enhancements play a crucial role in effective management of pharmacovigilance. Technology fosters collaboration between disparate teams, enables seamless flow of data, intuitive collection, processing and analysis of data. Cumulatively, effective combination of domain expertise, agile process and robust technology has allowed us to consistently demonstrate time savings, high quality, cost reductions, increased efficiency and absolute compliance.
The  whitepaper examines the use of scientific expertise, LEAN process and technology to deliver enhanced efficiency and compliance.
Video
Encouraging Vaccine Adoption Among Children
In this short Pharm Exec TV episode, Linda Yu-Sing Fu, MD, of the Children’s National Medical Center and winner of a PhRMA Research & Hope Award, discusses the challenges for increasing vaccination among children ...View here
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
Technology
Nanotech: Big Stakes in Small Things
While nanomedicine may offer patients a better clinical outcome than regular drug therapy, its future depends on resolving issues that the familiar Big Pharma business model has been slow to address, writes William Looney ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
Digital Pharma
Seeing Beyond the Big Data Backlash
Is ‘Big Data’ just BS? Peter Houston looks beyond the hype to reveal what companies should be focusing on ...Read more
|
